AstraZeneca Pharma India Sets Q2 FY27 Results Meeting for Nov 5

AstraZeneca Pharma India Limited will consider its unaudited Q2 and first-half FY27 financial results at a board meeting on November 5, 2026, after reporting Q1 revenue from operations of ₹682.8 crore, up 29.7% year-on-year, and net profit of ₹37.9 crore, down 32.1%.

When will AstraZeneca Pharma India announce Q2 FY27 results?

AstraZeneca Pharma India has scheduled a board meeting for November 5, 2026, to approve unaudited financial results for the quarter and half-year ended September 30, 2026. The company has disclosed that its trading window will remain closed from September 16 until November 7, 2026.

The meeting covers the July-September 2026 quarter, or Q2 FY27, as well as the six-month period from April through September 2026. The available corporate-action information states that the figures had not yet been filed at the time of the announcement. As a result, the scheduled meeting should not be treated as confirmation of revenue, profit, or any other performance metric for Q2.

Under Indian listing requirements, companies are required to publish quarterly financial results within the prescribed period after the end of the quarter. For the September 2026 quarter, November 14, 2026 was cited as the outer reporting deadline. AstraZeneca Pharma India's November 5 meeting places its planned consideration ahead of that date.

What did AstraZeneca Pharma India report in Q1 FY27?

AstraZeneca Pharma India reported revenue from operations of ₹682.8 crore in Q1 FY27, representing growth of 29.7% from the comparable year-earlier quarter. The company said the increase was driven by performance in its core Oncology and Biopharmaceutical therapy areas.

Net profit for the April-June 2026 quarter was ₹37.9 crore, down 32.1% year-on-year. This means that revenue growth did not translate into a year-on-year increase in reported profit in the quarter. The information provided does not specify the expense, tax, pricing, or other factors behind the movement in net profit.

The contrast between sales growth and profit decline will be relevant when the company releases its Q2 and first-half figures. Investors will be able to compare the new disclosure with the first quarter's ₹682.8 crore revenue and ₹37.9 crore net profit, rather than relying on unverified estimates or figures circulating before the filing.

What is the year-earlier base for the September quarter?

The September 2025 quarter provides the reported comparison base for Q2 FY27. AstraZeneca Pharma India recorded revenue of ₹559 crore and net profit of ₹54 crore in Q2 FY26, according to the information available with the results preview.

That earlier quarter was marked by stronger reported growth, with total income rising 35.8% year-on-year to ₹565.26 crore and profit after tax increasing 41.1% to ₹54.22 crore. Revenue for that period was reported at ₹559.09 crore. All figures in this report are presented in crore for consistency.

The company also reported that Oncology led growth in Q2 FY26, with revenue in the therapy area increasing 48.6%. It received seven regulatory approvals and launched Eculizumab during that period, expanding its product portfolio. These developments form part of the operating context against which investors may assess the September 2026 quarter.

What figures will investors compare after the board meeting?

Investors will compare the Q2 FY27 filing with both the ₹559 crore Q2 FY26 revenue base and the most recently reported Q1 FY27 revenue of ₹682.8 crore. They will also assess whether net profit moves from the ₹37.9 crore reported in Q1 FY27 and how it compares with the ₹54 crore earned in Q2 FY26.

The available corporate-action data also places AstraZeneca Pharma India's market capitalisation at more than ₹15,920 crore. Market participants will have a confirmed basis to evaluate the company only after the board-approved results are filed with the stock exchanges.

The company announced a new Mumbai corporate office on October 16, 2026, describing the move as part of its next phase of growth through innovation. That announcement does not provide a quantified financial impact, but it is among the recent corporate developments preceding the Q2 results meeting.

Why do the Q2 FY27 results matter for AstraZeneca Pharma India investors?

The Q2 FY27 results matter because they will show whether the revenue momentum reported in the first quarter continued through the first half of the financial year. The results will also provide the next official update on profitability after Q1 revenue increased while net profit declined year-on-year.

The release is relevant for investors following the company's exposure to Oncology and Biopharmaceutical therapies, which were identified as the drivers of Q1 operational revenue growth. Regulatory approvals and product launches can also be important operating markers for pharmaceutical companies, although the provided information gives no FY27 forecast or guidance.

Until the filing is released, there is no verified Q2 FY27 revenue or profit number in the disclosed board-meeting information. The appropriate reference points remain the reported Q1 FY27 figures and the Q2 FY26 comparison base. Any claimed Q2 result that is not supported by the company’s exchange filing should be treated cautiously.

Conclusion

AstraZeneca Pharma India will consider its Q2 and H1 FY27 unaudited results on November 5, with the trading window closed through November 7. The key reported starting point is Q1 FY27, when revenue rose 29.7% to ₹682.8 crore while net profit declined 32.1% to ₹37.9 crore.

The next item to watch is the board-approved exchange filing for the quarter ended September 30, 2026. It will provide the confirmed Q2 and first-half revenue and profitability figures, allowing comparison with the ₹559 crore revenue and ₹54 crore net profit reported in Q2 FY26.